" /> Onvansertib - CISMeF





Preferred Label : Onvansertib;

NCIt synonyms : Polo-like Kinase 1 Inhibitor PCM-075; PLK-1 Inhibitor PCM-075; PLK1 Inhibitor PCM-075; Polo-like Kinase 1 Inhibitor NMS-1286937;

NCIt definition : An orally bioavailable, adenosine triphosphate (ATP) competitive inhibitor of polo-like kinase 1 (PLK1; PLK-1; STPK13), with potential antineoplastic activity. Upon administration, onvansertib selectively binds to and inhibits PLK1, which disrupts mitosis and induces selective G2/M cell-cycle arrest followed by apoptosis in PLK1-overexpressing tumor cells. PLK1, named after the polo gene of Drosophila melanogaster, is a serine/threonine kinase that is crucial for the regulation of mitosis, and plays a key role in tumor cell proliferation. PLK1 expression is upregulated in a variety of tumor cell types and high expression is associated with increased aggressiveness and poor prognosis.;

UNII : 67RM91WDHQ;

InChIKey : QHLVBNKYJGBCQJ-UHFFFAOYSA-N;

CAS number : 1034616-18-6;

Molecule name : PCM-075; PCM 075; NMS-1286937;

NCI Metathesaurus CUI : CL541611;

Details


Keyword's position in hierarchy(ies) : arborescence

You can consult :


Nous contacter.
02/05/2025


[Home] [Top]

© Rouen University Hospital. Any partial or total use of this material must mention the source.